UY35424A - Xantinas sustituidas y métodos para su uso - Google Patents

Xantinas sustituidas y métodos para su uso

Info

Publication number
UY35424A
UY35424A UY0001035424A UY35424A UY35424A UY 35424 A UY35424 A UY 35424A UY 0001035424 A UY0001035424 A UY 0001035424A UY 35424 A UY35424 A UY 35424A UY 35424 A UY35424 A UY 35424A
Authority
UY
Uruguay
Prior art keywords
methods
xantinas
replaced
trpc5
inhibiting
Prior art date
Application number
UY0001035424A
Other languages
English (en)
Inventor
Chenard Bertrand
Spencer David Kimball;
Gallaschun Randall
Original Assignee
Hydra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Inc filed Critical Hydra Biosciences Inc
Publication of UY35424A publication Critical patent/UY35424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos, composiciones y métodos para inhibir el canal iónico TRPC5 y los trastornos relacionados con TRPC5.
UY0001035424A 2013-03-14 2014-03-13 Xantinas sustituidas y métodos para su uso UY35424A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784448P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
UY35424A true UY35424A (es) 2014-10-31

Family

ID=50819943

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035424A UY35424A (es) 2013-03-14 2014-03-13 Xantinas sustituidas y métodos para su uso

Country Status (7)

Country Link
US (2) US20140275528A1 (es)
EP (1) EP2970316B1 (es)
JP (1) JP2016513687A (es)
AR (1) AR095561A1 (es)
TW (1) TW201444844A (es)
UY (1) UY35424A (es)
WO (1) WO2014152287A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016086008A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule aldehyde dehydrogenase inhibitors and methods of use thereof
CN110573509B (zh) * 2017-02-28 2023-05-26 北京生命科学研究所 Mlkl抑制剂
GB201712110D0 (en) * 2017-07-27 2017-09-13 Thomas Helledays Stiftelse För Medicinsk Forskning New compounds and uses
CA3075727A1 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
AU2019231208A1 (en) * 2018-03-05 2020-09-17 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
AU2020240059A1 (en) * 2019-03-20 2021-10-28 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN113603690B (zh) * 2021-08-02 2022-10-25 南开大学 一种含黄嘌呤-8-基的(e)-丙烯酸衍生物及其制备方法和应用
CN115636831A (zh) * 2022-10-27 2023-01-24 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1963325A2 (en) * 2005-12-07 2008-09-03 UCB Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法

Also Published As

Publication number Publication date
US20160145257A1 (en) 2016-05-26
AR095561A1 (es) 2015-10-28
TW201444844A (zh) 2014-12-01
US20140275528A1 (en) 2014-09-18
EP2970316B1 (en) 2017-11-08
WO2014152287A3 (en) 2014-12-04
JP2016513687A (ja) 2016-05-16
WO2014152287A9 (en) 2015-04-23
EP2970316A2 (en) 2016-01-20
WO2014152287A2 (en) 2014-09-25
WO2014152287A4 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
UY35488A (es) Xantinas sustituidas y métodos para su uso
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
UY35424A (es) Xantinas sustituidas y métodos para su uso
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
DK3596123T3 (da) FC-optimeret anti-CD25 til tumorspecifik celledepletering
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201891211A1 (ru) Ингибиторы cxcr2
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
CR20160419A (es) Nuevos compuestos biciclicos
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
DK3215618T3 (da) Transposasesammensætninger til reduktion af insertionsbias
BR112015023310A2 (pt) composições, métodos e kits para redução de níveis lipídicos
DK2986726T3 (da) Hidtil ukendte bacillusstammesammensætninger
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
EP3355989A4 (en) COMPOSITION WITH IMPROVED EFFICIENCY
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
DK3298668T3 (da) På jorden anbragt kanal
DK3576719T3 (da) Misbrugsafskrækkende formuleringer på basis af amfetamin
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
DK3899996T3 (da) Elektrolytsammensætninger

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112